Lynx1 Capital Management LP 13D and 13G filings for Neoleukin Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-14 09:19 am Sale | 2023-12-31 | 13G | Neoleukin Therapeutics, Inc. NLTX | Lynx1 Capital Management LP | 46 0.100% | -114,511 (-99.96%) | Filing |
| 2022-12-30 4:29 pm Purchase | 2022-12-20 | 13G | Neoleukin Therapeutics, Inc. NLTX | Lynx1 Capital Management LP | 114,557 5.380% | 114,557 (New Position) | Filing |